GW Pharmaceuticals to Present at Lazard Healthcare Conference in New York

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Nov 12, 2012

Porton Down, UK; 12 November 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that its Managing Director, Justin Gover will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference in New York on Tuesday, 13 November 2012 at 11.30am EST (4.30pm GMT). A live webcast will be accessible via the investor relations section of the GW website.

Enquiries:

GW Pharmaceuticals plc 

(Today) + 44 20 7831 3113 Dr Geoffrey Guy, Chairman 

(Thereafter) + 44 1980 557000 Justin Gover, Managing Director   

FTI Consulting  

+ 44 20 7831 3113 Ben Atwell / John Dineen / Simon Conway    

Peel Hunt LLP  

+44 (0)20 7418 8900 James Steel / Vijay Barathan 

Note to Editors

About GW GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com

Recent News